Low persistence of anticholinergic drug use in Sweden
- 127 Downloads
The frequency and severity of urge incontinence and overactive bladder in a population increase with advancing age [1, 2]. The initial treatment for patients seeking medical care for these symptoms is often bladder training. Subsequent treatment with anticholinergic agents may be initiated in the absence of a sufficient treatment effect by bladder training alone.
There is evidence that treatment with anticholinergics for urge incontinence provides beneficial effects on disease-specific quality of life . However, these effects are small in many cases, and mild adverse effects are common. Only a proportion of patients are therefore satisfied with the effect of the treatment [4, 5].
The anticholinergic drugs provided in Sweden are oxybutynin (tablets, patches), tolterodine, solifenacin, darifenacin and fesoterodine. All products except oxybutynin (tablets) are originator products without generic competition and are more costly than the generic oxybutynin. During the last 10 years...
KeywordsAdherence Rate Oxybutynin Urge Incontinence Tolterodine Anticholinergic Drug
Mikael Hoffmann at NEPI, The Swedish Foundation for Pharmacoepidemiology
- 2.Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the epic study. Eur Urol 50(6):1306–1314, discussion 1314-1305PubMedCrossRefGoogle Scholar
- 3.Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J (2006) Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev (Online) 4:CD003781Google Scholar
- 6.Hay-Smith J, Herbison P, Ellis G, Morris A (2005) Cochrane Database Syst Rev(Online) 3:CD005429Google Scholar
- 8.Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundstrom A, Westerholm B, Rosen M (2007) The new Swedish prescribed drug register—opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16(7):726–735PubMedCrossRefGoogle Scholar